Drugs

, Volume 67, Issue 18, pp 2697–2716 | Cite as

Treatment of Lysosomal Storage Disorders

Progress with Enzyme Replacement Therapy
Review Article

Abstract

Enzyme replacement therapy (ERT) as treatment for lysosomal storage diseases (LSDs) was suggested as long ago as 1966 by De Duve and Wattiaux. However, it took >35 years to demonstrate the safety and effectiveness of ERT for type 1 Gaucher’s disease. An important breakthrough was certainly the enactment of legislation in the US, designed to encourage commercialisation of products developed in academic institutions for pharmaceutical companies to invest in treatments for rare diseases. The principles elaborated in the development of the treatment of Gaucher’s disease were subsequently applied to the development of ERT of other LSDs. The safety and effectiveness of ERT for Fabry’s disease, mucopolysaccharidoses (MPS) I, MPS II and MPS VI, as well as for Pompe’s disease have been demonstrated in well designed clinical trials, and the treatments are now commercially available throughout the world. Several questions remain to be answered. The long-term effectiveness of most of the treatments has not yet been established. What is reversible by ERT and what may not be reversible but is preventable, is not yet clear. The pathology in some tissues, such as the brain, is inaccessible to ERT, indicating that some manifestations of the LSD will not respond to the treatment. The extent of this problem is still unclear. The cost of ERT is very high, creating problems for third-party payers, which has strained reimbursement schemes based on the demonstration of acceptable cost effectiveness. ERT of LSDs represents the most important advance in the treatment of this class of diseases. The information that is currently being collected as part of large-scale observational studies will help to establish the full potential of the treatment.

Keywords

Enzyme Replacement Therapy Miglustat Alglucerase Substrate Reduction Therapy Imiglucerase 

Notes

Acknowledgements

Dr Clarke has received research grants, unrestricted educational grants and honoraria for scientific and continuing medical education presentations regarding the management of lysosomal storage diseases from Genzyme Corporation, Genzyme Canada, Shire Human Genetic Therapies and Actelion Pharmaceuticals, Canada. He also receives honoraria for service on advisory boards sponsored by the same companies regarding the management of lysosomal storage diseases. Dr Rohrbach has no conflicts of interest that are directly relevant to the content of this review. No sources of funding were used to assist in the preparation of this review.

References

  1. 1.
    Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 2004 Jul; 5(7): 554–65PubMedCrossRefGoogle Scholar
  2. 2.
    Elleder M. Glucosylceramide transfer from lysosomes: the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data. J Inherit Metab Dis 2006 Dec; 29(6): 707–15PubMedCrossRefGoogle Scholar
  3. 3.
    De Duve C, Wattiaux R. Functions of lysosomes. Annu Rev Physiol 1966; 28: 435–92PubMedCrossRefGoogle Scholar
  4. 4.
    Bright NA, Reaves BJ, Mullock BM, et al. Dense core lysosomes can fuse with late endosomes and are re-formed from the resultant hybrid organelles. J Cell Sci 1997 Sep; 110 (Pt 17): 2027–40PubMedGoogle Scholar
  5. 5.
    Stinchcombe JC, Page LJ, Griffiths GM. Secretory lysosome biogenesis in cytotoxic T lymphocytes from normal and Chediak Higashi syndrome patients. Traffic 2000 May; 1(5): 435–44PubMedCrossRefGoogle Scholar
  6. 6.
    Gu F, Gruenberg J. Biogenesis of transport intermediates in the endocytic pathway. FEBS Lett 1999 Jun 4; 452 (1-2): 61–6PubMedCrossRefGoogle Scholar
  7. 7.
    Sabatini DD, Adesnik MB. The biogenesis of membranes and organelles. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001: 433–517Google Scholar
  8. 8.
    Kornfeld S. Lysosomal enzyme targeting. Biochem Soc Trans 1990 Jun; 18(3): 367–74PubMedGoogle Scholar
  9. 9.
    Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 2003 Mar; 4(3): 202–12PubMedCrossRefGoogle Scholar
  10. 10.
    Reitman ML, Lang L, Kornfeld S. UDP-N-acetylglucosamine: lysosomal enzyme N-acetylglucosamine-1-phosphotransferase. Methods Enzymol 1984; 107: 163–72PubMedCrossRefGoogle Scholar
  11. 11.
    Waheed A, Hasilik A, von Figura K. Processing of the phosphorylated recognition marker in lysosomal enzymes: characterization and partial purification of a microsomal alpha-N-acetylglucosaminyl phosphodiesterase. J Biol Chem 1981 Jun 10; 256(11): 5717–21PubMedGoogle Scholar
  12. 12.
    Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001: 3421–52Google Scholar
  13. 13.
    Desnick RJ. Enzyme therapy in genetic diseases: II. New York: Alan R. Liss, 1980Google Scholar
  14. 14.
    Desnick RJ, Bernlohr RW, Krivit W. Enzyme therapy in genetic diseases, birth defects. New York: The National Foundation, 1973Google Scholar
  15. 15.
    Brady RO, Murray GJ, Barton NW. Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease. J Inherit Metab Dis 1994; 17(4): 510–9PubMedCrossRefGoogle Scholar
  16. 16.
    Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem Biophys Res Commun 1965 Jan 18; 18: 221–5Google Scholar
  17. 17.
    Di Rocco M, Allegri AE, Grossi S, et al. Gaucher disease phenotype. J Pediatr 2004 Dec; 145(6): 860PubMedGoogle Scholar
  18. 18.
    Zimran A, Gelbart T, Westwood B, et al. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet 1991; 49: 855–9PubMedGoogle Scholar
  19. 19.
    Brady RO, Kanfer JN, Bradley RM, et al. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher’s disease. J Clin Invest 1966 Jul; 45(7): 1112–5PubMedCrossRefGoogle Scholar
  20. 20.
    Brady RO, Tallman JF, Johnson WG, et al. Replacement therapy for inherited enzyme deficiency: use of purified ceramide-trihexosidase in Fabry’s disease. N Engl J Med 1973 Jul 5; 289(1): 9–14PubMedCrossRefGoogle Scholar
  21. 21.
    Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 1991 May 23; 324(21): 1464–70PubMedCrossRefGoogle Scholar
  22. 22.
    Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995 Jan 1; 122(1): 33–9PubMedGoogle Scholar
  23. 23.
    Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002 Aug 1; 113(2): 112–9PubMedCrossRefGoogle Scholar
  24. 24.
    Grabowski GA. Gaucher disease: lessons from a decade of therapy. J Pediatr 2004 May; 144 (5 Suppl.): S15–9PubMedCrossRefGoogle Scholar
  25. 25.
    Kaplan P, Mazur A, Manor O, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996 Jul; 129(1): 149–53PubMedCrossRefGoogle Scholar
  26. 26.
    Kauli R, Zaizov R, Lazar L, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2000 Feb; 2(2): 158–63PubMedGoogle Scholar
  27. 27.
    Starzyk K, Richards S, Yee J, et al. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab 2007 Feb; 90(2): 157–63PubMedCrossRefGoogle Scholar
  28. 28.
    Beutler E. Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab 2006 Jul; 88(3): 208–15PubMedCrossRefGoogle Scholar
  29. 29.
    Clarke JT. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ 2006 Jan 17; 174(2): 189–90PubMedCrossRefGoogle Scholar
  30. 30.
    Schiffmann R, Heyes MP, Aerts JM, et al. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher’s disease. Ann Neurol 1997 Oct; 42(4): 613–21PubMedCrossRefGoogle Scholar
  31. 31.
    Altarescu G, Hill S, Wiggs E, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease. J Pediatr 2001 Apr; 138(4): 539–47PubMedCrossRefGoogle Scholar
  32. 32.
    Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000 Apr 29; 355(9214): 1481–5PubMedCrossRefGoogle Scholar
  33. 33.
    Prows CA, Sanchez N, Daugherty C, et al. Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet 1997 Jul 11; 71(1): 16–21PubMedCrossRefGoogle Scholar
  34. 34.
    Zimran A, Hollak CE, Abrahamov A, et al. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood 1993 Aug 15; 82(4): 1107–9PubMedGoogle Scholar
  35. 35.
    Cox TM, Aerts JM, Andria G, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003; 26(6): 513–26PubMedCrossRefGoogle Scholar
  36. 36.
    Weinreb NJ, Barranger JA, Charrow J, et al. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 2005 Nov; 80(3): 223–9PubMedCrossRefGoogle Scholar
  37. 37.
    Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 2002 Jun; 13 Suppl. 2: S139–43PubMedGoogle Scholar
  38. 38.
    Kampmann C, Baehner F, Ries M, et al. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol 2002 Jun; 13 Suppl. 2: S147–9PubMedGoogle Scholar
  39. 39.
    Goldman ME, Cantor R, Schwartz MF, et al. Echocardiographic abnormalities and disease severity in Fabry’s disease. J Am Coll Cardiol 1986 May; 7(5): 1157–61PubMedCrossRefGoogle Scholar
  40. 40.
    Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J 2000 Jun; 139(6): 1101–8PubMedCrossRefGoogle Scholar
  41. 41.
    Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol 1996 Jul; 40(1): 8–17PubMedCrossRefGoogle Scholar
  42. 42.
    Mendez MF, Stanley TM, Medel NM, et al. The vascular dementia of Fabry’s disease. Dement Geriatr Cogn Disord 1997 Jul–Aug; 8(4): 252–7PubMedCrossRefGoogle Scholar
  43. 43.
    Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001 Jun 6; 285(21): 2743–9PubMedCrossRefGoogle Scholar
  44. 44.
    Sirrs SM, Clarke JTR. Agalsidase alpha therapy for Fabry disease. Expert Rev Endocrinol Metab 2007; 2(2): 147–54CrossRefGoogle Scholar
  45. 45.
    Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001 Mar; 68(3): 711–22PubMedCrossRefGoogle Scholar
  46. 46.
    Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A: replacement therapy in Fabry’s disease. N Engl J Med 2001 Jul 5; 345(1): 9–16PubMedCrossRefGoogle Scholar
  47. 47.
    Thurberg BL, Randolph Byers H, Granter SR, et al. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies. J Invest Dermatol 2004 Apr; 122(4): 900–8PubMedCrossRefGoogle Scholar
  48. 48.
    Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004 Jul; 75(1): 65–74PubMedCrossRefGoogle Scholar
  49. 49.
    Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007 Jan 16; 146(2): 77–86PubMedGoogle Scholar
  50. 50.
    Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002 Dec; 62(6): 1933–46PubMedCrossRefGoogle Scholar
  51. 51.
    Gupta S, Ries M, Kotsopoulos S, et al. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 2005 Sep; 84(5): 261–8CrossRefGoogle Scholar
  52. 52.
    Vedder AC, Linthorst GE, van Breemen MJ, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007 Feb; 30(1): 68–78PubMedCrossRefGoogle Scholar
  53. 53.
    Clarke JT. Narrative review: Fabry disease. Ann Intern Med 2007 Mar 20; 146(6): 425–33PubMedGoogle Scholar
  54. 54.
    Linthorst GE, Hollak CE, Donker-Koopman WE, et al. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004 Oct; 66(4): 1589–95PubMedCrossRefGoogle Scholar
  55. 55.
    Elleder M, Poupetova H, Kozich V. Fetal pathology in Fabry’s disease and mucopolysaccharidosis type I [in Czech]. Cesk Patol 1998 Jan; 34(1): 7–12PubMedGoogle Scholar
  56. 56.
    Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003 Feb 18; 138(4): 338–46PubMedGoogle Scholar
  57. 57.
    Lowry RB, Applegarth DA, Toone JR, et al. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet 1990 Aug; 85(3): 389–90PubMedCrossRefGoogle Scholar
  58. 58.
    Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999 Jan 20; 281(3): 249–54PubMedCrossRefGoogle Scholar
  59. 59.
    Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet 1997 Dec; 101(3): 355–8PubMedCrossRefGoogle Scholar
  60. 60.
    Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999 Jul–Aug; 105(1–2): 151–6PubMedGoogle Scholar
  61. 61.
    Scott HS, Bunge S, Gal A, et al. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat 1995; 6(4): 288–302PubMedCrossRefGoogle Scholar
  62. 62.
    Whitley CB, Belani KG, Chang PN, et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet 1993 Apr 15; 46(2): 209–18PubMedCrossRefGoogle Scholar
  63. 63.
    Vellodi A, Young EP, Cooper A, et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child 1997 Feb; 76(2): 92–9PubMedCrossRefGoogle Scholar
  64. 64.
    Peters C, Shapiro EG, Anderson J, et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 1998 Apr 1; 91(7): 2601–8Google Scholar
  65. 65.
    Guffon N, Souillet G, Maire I, et al. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 1998 Jul; 133(1): 119–25PubMedCrossRefGoogle Scholar
  66. 66.
    Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001 Jan 18; 344(3): 182–8PubMedCrossRefGoogle Scholar
  67. 67.
    Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004 May; 144(5): 581–8PubMedCrossRefGoogle Scholar
  68. 68.
    Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006 Aug; 8(8): 465–73PubMedCrossRefGoogle Scholar
  69. 69.
    Muenzer J, Gucsavas-Calikoglu M, McCandless SE, et al. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 2007 Mar; 90(3): 329–37PubMedCrossRefGoogle Scholar
  70. 70.
    Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004 May; 144(5): 574–80PubMedCrossRefGoogle Scholar
  71. 71.
    Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, openlabel extension study. J Pediatr 2006 Apr; 148(4): 533–9PubMedCrossRefGoogle Scholar
  72. 72.
    Krivit W, Pierpont ME, Ayaz K, et al. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): biochemical and clinical status 24 months after transplantation. N Engl J Med 1984 Dec 20; 311(25): 1606–11PubMedCrossRefGoogle Scholar
  73. 73.
    Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: Mc-Graw-Hill, 2001: 3389–420Google Scholar
  74. 74.
    Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004 May; 144 (5 Suppl.): S35–43PubMedCrossRefGoogle Scholar
  75. 75.
    Gambetti P, DiMauro S, Baker L. Nervous system in Pompe’s disease: ultrastructure and biochemistry. J Neuropathol Exp Neurol 1971 Jul; 30(3): 412–30PubMedCrossRefGoogle Scholar
  76. 76.
    Sakurai I, Tosaka A, Mori Y, et al. Glycogenosis type II (Pompe): the fourth autopsy case in Japan. Acta Pathol Jpn 1974 Nov; 24(6): 829–46PubMedGoogle Scholar
  77. 77.
    Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006 May; 148(5): 671–6PubMedCrossRefGoogle Scholar
  78. 78.
    Van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003 Aug; 112(2): 332–40PubMedCrossRefGoogle Scholar
  79. 79.
    Jongen SP, Gerwig GJ, Leeflang BR, et al. N-glycans of recombinant human acid alpha-glucosidase expressed in the milk of transgenic rabbits. Glycobiology 2007 Jun; 17(6): 600–19PubMedCrossRefGoogle Scholar
  80. 80.
    Bijvoet AG, Van Hirtum H, Kroos MA, et al. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 1999 Nov; 8(12): 2145–53PubMedCrossRefGoogle Scholar
  81. 81.
    Van den Hout H, Reuser AJ, Vulto AG, et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000 Jul 29; 356(9227): 397–8PubMedCrossRefGoogle Scholar
  82. 82.
    Van den Hout JM, Reuser AJ, de Klerk JB, et al. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001 Apr; 24(2): 266–74PubMedCrossRefGoogle Scholar
  83. 83.
    Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004 May; 113(5): e448–57PubMedCrossRefGoogle Scholar
  84. 84.
    Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005 Jan; 15(1): 24–31PubMedCrossRefGoogle Scholar
  85. 85.
    Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006 Jul; 149(1): 89–97PubMedCrossRefGoogle Scholar
  86. 86.
    Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001 Mar–Apr; 3(2): 132–8PubMedGoogle Scholar
  87. 87.
    Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007 Jan 9; 68(2): 99–109PubMedCrossRefGoogle Scholar
  88. 88.
    Schiffmann R, Murray GJ, Treco D, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000 Jan 4; 97(1): 365–70PubMedCrossRefGoogle Scholar
  89. 89.
    Kakkis ED, Schuchman E, He X, et al. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 2001 Mar; 72(3): 199–208PubMedCrossRefGoogle Scholar
  90. 90.
    Lachmann RH, te Vruchte D, Lloyd-Evans ER, et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis 2004 Aug; 16(3): 654–8PubMedCrossRefGoogle Scholar
  91. 91.
    Russell C, Hendson G, Jevon G, et al. Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet 1998 May; 53(5): 349–61PubMedCrossRefGoogle Scholar
  92. 92.
    Jeyakumar M, Thomas R, Elliot-Smith E, et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 2003 Apr; 126 (Pt 4): 974–87PubMedCrossRefGoogle Scholar
  93. 93.
    Wada R, Tifft CJ, Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci U S A 2000 Sep 26; 97(20): 10954–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Division of Clinical and Metabolic GeneticsHospital for Sick ChildrenTorontoCanada
  2. 2.Service de Génétique MédicaleCentre Hospitalier Universitaire de SherbrookeSherbrookeCanada

Personalised recommendations